Mutations in these DNA repair genes have been approved to determine the usage of poly (ADP‐ribose) polymerase inhibitor (PARPi) for patients with advanced prostate cancer, where CH mutations might induce misdiagnosis. The gene discussed is C4B; the disease is prostate carcinoma.